RG6524
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 14, 2023
A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models
(AACR 2023)
- "We therefore developed a DLL3/CD3/CD137 trispecific T cell engager composed of two CD3/CD137 dual specific Fabs and one extra DLL3 Fab (DLL3 trispecific, RG6524). We initially investigated the CD3 and CD137 signal transduction in Jurkat cells harboring NFAT or NF-κB reporter cocultured with DLL3 positive cells...Likewise, tocilizumab treatment did not reduce the efficacy, suggesting that CRS mitigation did not abrogate the therapeutic benefit.We finally assessed the tolerability in non-human primates. Our data showed that DLL3 trispecific has potent activity and is well suited for clinical application in SCLC. These findings provide a rationale for the clinical testing of DLL3 trispecific."
IO biomarker • Preclinical • Trispecific • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CD8 • DLL3 • IFNG • NF-κβ • TNFRSF9
February 02, 2023
"And 6 new projects in the clinic for $RHHBY, incl 2 undisclosed mechanisms in oncology: RG6524 (=RO7616789) FPI Jan 2023 https://t.co/qNRZpOUvjW RG6411 (=RO7502175) FPI Q4 2022 https://t.co/p48EaRVy85"
(@JacobPlieth)
Oncology
December 01, 2022
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
(clinicaltrials.gov)
- P1 | N=168 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting
Enrollment open • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor
November 17, 2022
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
(clinicaltrials.gov)
- P1 | N=168 | Not yet recruiting | Sponsor: Hoffmann-La Roche
New P1 trial • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1